NCT06817629

Brief Summary

The driving pressure (DP) is defined as the pressure above the end-expiratory pressure (PEEP) required to distend the respiratory system by the tidal volume (Vt). It is calculated as follows: DP = Plateau pressure - PEEP. It is also equal to the ratio between the tidal volume and the compliance of the respiratory system (Crs): DP = Vt/Crs. Crs is correlated with end-expiratory lung volume, i.e., the lung volume available to receive the tidal volume. DP allows adaptation of the Vt to the available lung volume when the lungs are diseased, rather than to a fraction of lung size when they are healthy, as occurs when tidal volume is adjusted in mL/kg of predicted body weight (PBW). DP is therefore a better reflection of the deformation applied by the tidal volume and the risk of overdistension. It is an important prognostic indicator in acute respiratory distress syndrome (ARDS), with a risk of excess mortality when DP exceeds 14 cm H2O. Conversely, an excessively low DP, suggesting a low tidal volume in relation to the available lung volume, may theoretically also be accompanied by deleterious effects: de-recruitment, atelectrauma, the need to increase respiratory rate, the need for significant sedation, or even curarization. DP and Vt can influence hemodynamics, as overdistension is associated with an increase in dead space and the occurrence of acute cor pulmonale. On the other hand, de-recruitment due to low tidal volume can lead to hypoxic vasoconstriction with an increase in right ventricular afterload.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
9mo left

Started Mar 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress62%
Mar 2025Apr 2027

First Submitted

Initial submission to the registry

January 7, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 10, 2025

Completed
21 days until next milestone

Study Start

First participant enrolled

March 3, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2027

Expected
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 2, 2027

Last Updated

February 10, 2025

Status Verified

February 1, 2025

Enrollment Period

2 years

First QC Date

January 7, 2025

Last Update Submit

February 5, 2025

Conditions

Keywords

ARDSV/Q ratiosHemodynamic

Outcome Measures

Primary Outcomes (1)

  • distribution of perfusion and ventilation across VA/Q ratios zones, wasted ventilation and perfusion.

    demonstration that ventilate patient with ARDS with an objective of protective driving pressure vent may change VA/Q ratio by using electrical impedance tomography

    24 hours

Secondary Outcomes (2)

  • DP-vent may induce a modification in patient with right ventricular

    24 hours

  • Change in right ventricular systolic function parameters

    24 hours

Interventions

To ventilated patients with ARDS with an objective of driving pressure than a tidal volume set on predicted body weight

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with ARDS under deep sedation +/- paralized

You may qualify if:

  • Age ≥ 18 years
  • ARDS moderate to severe according to the Berlin criteria
  • Patient receiving continuous sedation and curarization
  • Free and informed consent from the patient or family member

You may not qualify if:

  • Pregnancy
  • Adult patient subject to a legal protection measure (tutor, curator, etc.)
  • Patients with a pacemaker, automatic implantable cardioverter defibrillator,
  • Contraindications to thoracic belt placement (e.g., thoracic or spinal cord trauma, recent thoracic surgery)
  • Undrained pneumothorax, bronchopleural fistula
  • Hemodynamic instability (i.e., use of intravenous fluids of more than 10 mL/kg or vasopressors 2 mg/h of norepinephrine or 0.5 mg/h of epinephrine)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assistance Publique Hôpitaux de Paris - CHU HENRI MONDOR

Créteil, 94010, France

Location

MeSH Terms

Interventions

Hemodynamics

Intervention Hierarchy (Ancestors)

Cardiovascular Physiological PhenomenaCirculatory and Respiratory Physiological Phenomena

Central Study Contacts

Pascale LABEDADE, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 7, 2025

First Posted

February 10, 2025

Study Start

March 3, 2025

Primary Completion (Estimated)

March 5, 2027

Study Completion (Estimated)

April 2, 2027

Last Updated

February 10, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

Locations